^
    almost2years
    Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies (clinicaltrials.gov)
    P1/2, N=111, Recruiting, Georgiamune Inc | Not yet recruiting --> Recruiting
    Enrollment open
    |
    LAG3 (Lymphocyte Activating 3)
    |
    GIM-122
    2years
    Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies (clinicaltrials.gov)
    P1/2, N=111, Not yet recruiting, Georgiamune Inc
    New P1/2 trial • Metastases
    |
    LAG3 (Lymphocyte Activating 3)
    |
    GIM-122